A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
Authors
Keywords
-
Journal
BMC Neurology
Volume 18, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-11-09
DOI
10.1186/s12883-018-1193-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Migraine
- (2018) David W Dodick LANCET
- Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention
- (2018) Vladimir Skljarevski et al. JAMA Neurology
- Association Between Migraine and Suicidal Behaviors: A Nationwide Study in the USA
- (2017) Lauren E. Friedman et al. HEADACHE
- Erenumab (AMG 334) in episodic migraine
- (2017) Messoud Ashina et al. NEUROLOGY
- Long-Term Use and Safety of Migraine Preventive Medications
- (2016) Juliana VanderPluym et al. HEADACHE
- Topiramate in Migraine Prevention: A 2016 Perspective
- (2016) Stephen D. Silberstein HEADACHE
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2016) Theo Vos et al. LANCET
- Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example
- (2015) David W. Dodick et al. JOURNAL OF PAIN
- Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
- (2014) David W Dodick et al. LANCET NEUROLOGY
- Migraine and the Risk for Stroke and Cardiovascular Disease
- (2014) Simona Sacco et al. Current Cardiology Reports
- The International Classification of Headache Disorders, 3rd edition (beta version)
- (2013) CEPHALALGIA
- Noncancer Pain Conditions and Risk of Suicide
- (2013) Mark A. Ilgen et al. JAMA Psychiatry
- Migraine Headaches and Suicide Attempt
- (2012) Naomi Breslau et al. HEADACHE
- Assessing and Managing All Aspects of Migraine: Migraine Attacks, Migraine-Related Functional Impairment, Common Comorbidities, and Quality of Life
- (2012) Dawn C. Buse et al. MAYO CLINIC PROCEEDINGS
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1
- (2012) S.D. Silberstein et al. NEUROLOGY
- The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients
- (2012) Regina Rendas-Baum et al. QUALITY OF LIFE RESEARCH
- The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults
- (2011) Kelly Posner et al. AMERICAN JOURNAL OF PSYCHIATRY
- Prevention of episodic migraine with topiramate: a prospective 24-week, open-label, flexible-dose clinical trial with optional 24 weeks follow-up in a community setting
- (2010) R. Malessa et al. CURRENT MEDICAL RESEARCH AND OPINION
- EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force
- (2009) S. Evers et al. EUROPEAN JOURNAL OF NEUROLOGY
- Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting
- (2009) Gereon Nelles et al. JOURNAL OF HEADACHE AND PAIN
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation